Bali Body Bb Cream Spf 15 Tan

Octocrylene, Octinoxate, Avobenzone, Oxybenzone


Bali Body Pty Ltd
Human Otc Drug
NDC 70630-0030
Bali Body Bb Cream Spf 15 Tan also known as Octocrylene, Octinoxate, Avobenzone, Oxybenzone is a human otc drug labeled by 'Bali Body Pty Ltd'. National Drug Code (NDC) number for Bali Body Bb Cream Spf 15 Tan is 70630-0030. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Bali Body Bb Cream Spf 15 Tan drug includes Avobenzone - 30 mg/mL Octinoxate - 50 mg/mL Octocrylene - 60 mg/mL Oxybenzone - 30 mg/mL . The currest status of Bali Body Bb Cream Spf 15 Tan drug is Active.

Drug Information:

Drug NDC: 70630-0030
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Bali Body Bb Cream Spf 15 Tan
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Octocrylene, Octinoxate, Avobenzone, Oxybenzone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Bali Body Pty Ltd
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 30 mg/mL
OCTINOXATE - 50 mg/mL
OCTOCRYLENE - 60 mg/mL
OXYBENZONE - 30 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 25 Mar, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Bali Body Pty Ltd
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:9354477000201
UPC stands for Universal Product Code.
UNII:G63QQF2NOX
4Y5P7MUD51
5A68WGF6WM
95OOS7VE0Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
70630-0030-11 TUBE in 1 BOX (70630-0030-1) / 35 mL in 1 TUBE25 Mar, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose: sunscreen

Product Elements:

Bali body bb cream spf 15 tan octocrylene, octinoxate, avobenzone, oxybenzone fytic acid water propylene glycol ethylhexyl stearate cyclomethicone 5 glyceryl monostearate grape seed oil starch, tapioca cyclomethicone 6 cetostearyl alcohol potassium cetyl phosphate cetearyl olivate glycerin hyaluronate sodium green tea leaf eleuthero sorbitan olivate butylene glycol alcohol sodium hydroxide phenoxyethanol benzyl alcohol ethylhexylglycerin potassium sorbate mica ferric oxide yellow ferric oxide red ferrosoferric oxide titanium dioxide octocrylene octocrylene octinoxate octinoxate avobenzone avobenzone oxybenzone oxybenzone

Indications and Usage:

Use: helps prevent sunburn, if used with other sun protection measures decreases the risk of skin cancer.

Warnings:

Warnings: for external use only. keep out of direct sunlight or other sources of strong light. product to be stored between 5-28°c. discontinue use if irritation occurs. subtle variations in appearance and texture of this product in no way affect its integrity. keep out of reach of children. please refer to balibodyco.com for further sun-safety instructions.

Dosage and Administration:

Directions: apply to clean skin with fingertrips. layer for additional coverage.

Package Label Principal Display Panel:

Package labeling: bb cream tan rev


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.